Canaccord Genuity Maintains Buy on Health Catalyst, Raises Price Target to $3

Health Catalyst

Health Catalyst

HCAT

0.00

Canaccord Genuity analyst Richard Close maintains Health Catalyst (NASDAQ: HCAT) with a Buy and raises the price target from $2 to $3.